The global oncology company BeiGene has announced its intention to change its name to BeOne Medicines Ltd. This decision aligns with the company's commitment to developing innovative cancer treatments and partnering with the global community to reach as many patients as possible. The name change is pending shareholder approval, after which the company's stock ticker on Nasdaq will switch to ONC.
John V. Oyler, co-founder, chairman, and CEO of BeiGene, emphasized the company's mission: “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. Our focus is to not only bring innovative medicines to as many people as possible but also to identify and address the challenges that impede access, making treatments more accessible and affordable.”
Oyler noted that BeiGene has already assisted over 1.4 million patients and plans to introduce more than ten new potential medicines into clinical trials this year. He expressed optimism about the future: “I look forward to our next chapter of growth as BeOne.”
The rebranding is part of a broader strategic growth plan that has supported BeiGene's leadership in global oncology since its founding in 2010. Recently, the company reported $1 billion in quarterly revenue due to strong product sales in the U.S. and Europe.
To support its growing clinical portfolio and international expansion, BeiGene opened an $800 million flagship clinical R&D and manufacturing facility at Princeton West Innovation Campus in Hopewell last July.
With nearly 11,000 employees worldwide, BeiGene has advanced over 20 molecules into clinical trials and secured regulatory approvals across five continents. Its unique global clinical team conducts trials in more than 45 countries across Europe, North America, South America, Australia, and Asia.
BeiGene has established itself as a leader in hematology with BRUKINSA (zanubrutinib), which holds the broadest label among BTK inhibitors. In the U.S., it leads new patient starts for chronic lymphocytic leukemia both frontline and relapsed/refractory cases.
The company is advancing BRUKINSA as a monotherapy cornerstone for its hematology franchise while exploring combinations with late-stage BCL2 inhibitor sonrotoclax and BTK degrader BGB-16673.
Additionally, BeiGene aims to expand its leadership in solid tumors through TEVIMBRA (tislelizumab) while advancing assets for breast, lung, and gastrointestinal cancers using various modalities such as antibody-drug conjugates and targeted protein degraders.
